ASND
NASDAQAscendis Pharma A/S
Price$225.03-6.25 (-2.70%)
01:30 PM07:45 PM
News · 26 weeks72-44%
2025-10-262026-04-19
Mix5190d
- SEC Filings18(35%)
- Insider15(29%)
- Other13(25%)
- Earnings3(6%)
- Analyst2(4%)
Latest news
25 items- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior Notes due 2028 (the "notes") (CUSIP No. 04351P AD3 / ISIN No. US04351PAD33) for redemption on May 6, 2026 (the "Redemption Date"). Ascendis' redemption right in respect of the notes arises pursuant to Section 4.03(B) of the indenture (the "Indenture"), dated as of March 29, 2022, between Ascendis and U.S. Bank Trust Company, National Association, as trustee (the "Trustee"), as a result of the last reported sale price per ordinary share having exceeded 130% of the conversion pric
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- SECAmendment: SEC Form 8-A12B/A filed by Ascendis Pharma A/S8-A12B/A - Ascendis Pharma A/S (0001612042) (Filer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis Pharma Announces Commencement of Trading of its Ordinary Shares on NasdaqCOPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq), replacing the listing of American Depositary Shares (ADSs). The ordinary shares trade under the same ticker symbol "ASND" as previously used for the ADS listing. The ordinary shares trade under CUSIP number K08588103 and ISIN DK0060606333. On April 8, 2026, the Company announced plans to mandatorily exchange all outstanding ADSs for ordinary shares, with each ADS exchangeable for one ordinary share listed on the Nasdaq. The last trading day for ADSs on Nasdaq was April 17, 2026. As of Apri
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis Pharma to List Ordinary Shares Directly on Nasdaq- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held - Simplified listing structure intended to enable enhanced depth and breadth of ownership COPENHAGEN, Denmark, April 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that it plans to list its ordinary shares directly on Nasdaq, effective at the opening of trading on April 20, 2026. As part of the transition to a direct listing of ordinary shares on The Nasdaq Global Select Market, all outstanding ADSs will be exchanged for ordinary shares. E
- PRNew Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with Achondroplasia- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community - Enhanced improvements in spinal canal dimensions observed with TransCon CNP and TransCon hGH combination therapy compared to TransCon CNP monotherapy - For the TransCon CNP treatment-naïve cohort, the improvement in tibial femoral angle (TFA) indicated enhanced straightening of the legs - Children treated with long-term TransCon CNP monotherapy maintained TFA in normal range in COACH COPENHAGEN, Denmark, April 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating TransCon h
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- PRAscendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially available in the U.S. with revenue now recognized following approval of first patients and initiation of therapy COPENHAGEN, Denmark, April 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that YUVIWEL (navepegritide; developed as TransCon® CNP) was granted orphan drug exclusivity by the U.S. Food & Drug Administration (FDA) and that YUVIWEL is now commercially available in the United States. YUVIWEL is the first and only once-weekly treatment approved by FDA t
- INSIDERSEC Form 3 filed by new insider Bienaime Jean Jacques3 - Ascendis Pharma A/S (0001612042) (Issuer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- SECSEC Form 6-K filed by Ascendis Pharma A/S6-K - Ascendis Pharma A/S (0001612042) (Filer)
- INSIDERSEC Form 3 filed by new insider Fairey William3 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERSEC Form 3 filed by new insider Imani Siham3 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERSEC Form 3 filed by new insider Smith Scott Thomas3 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jensen Michael Wolff3 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bodenhoff Mads3 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERSEC Form 3 filed by new insider Pedersen Anni Lotte Kirstine Sonderbjerg3 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERSEC Form 3 filed by new insider Morrison Lisa3 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERSEC Form 3 filed by new insider Holtug Lars3 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sprogoe Kennett3 - Ascendis Pharma A/S (0001612042) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mikkelsen Jan Moller3 - Ascendis Pharma A/S (0001612042) (Issuer)